|Articles|July 24, 2008

FDA Launches Fellowship Program

The US Food and Drug Administration seeks applicants for its new Commissioner’s Fellowship Program for scientists, engineers, and health professionals. The two-year program will help prepare the agency to replace a large number of FDA staff who are preparing to retire as well as meet future goals.

Rockville, MD (July 17)-The US Food and Drug Administration is seeking applicants for its new Commissioner’s Fellowship Program for scientists, engineers, and health professionals. The two-year program will help prepare the agency to replace a large number of FDA staff who are preparing to retire as well as meet future goals. The first 30–40 participants will begin in October 2008.

“FDA is a science-based regulatory agency, and to fulfill our mission over the coming decade we will need to recruit thousands of highly skilled scientists and others with specialized and relevant expertise,” said Frank M. Torti, MD, MPH, principal deputy commissioner and chief scientist, in a prepared statement. “The FDA Commissioner’s Fellowship Program is designed to attract these people to the FDA and provide them with in-depth knowledge of the science that underpins regulatory decisions as we meet the challenges of both globalization and rapid changes in science and technology."

The coursework will be offered at the agency’s White Oak, Maryland, campus or at other FDA facilities chosen by the participant. The program centers on hands-on research and seminars in the sciences of regulatory review, including public policy, FDA law, epidemiology, clinical trials, statistics, devices, and radiological health.

To apply, a curriculum vitae and three references, including contact information, should be submitted to [email protected] by Aug. 29, 2008. Additional information is available on the FDA website.


Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.